JP2012046489A5 - - Google Patents

Download PDF

Info

Publication number
JP2012046489A5
JP2012046489A5 JP2011151340A JP2011151340A JP2012046489A5 JP 2012046489 A5 JP2012046489 A5 JP 2012046489A5 JP 2011151340 A JP2011151340 A JP 2011151340A JP 2011151340 A JP2011151340 A JP 2011151340A JP 2012046489 A5 JP2012046489 A5 JP 2012046489A5
Authority
JP
Japan
Prior art keywords
cancer
cells
virus
use according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011151340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012046489A (ja
Filing date
Publication date
Priority claimed from AU2002953436A external-priority patent/AU2002953436A0/en
Application filed filed Critical
Publication of JP2012046489A publication Critical patent/JP2012046489A/ja
Publication of JP2012046489A5 publication Critical patent/JP2012046489A5/ja
Pending legal-status Critical Current

Links

JP2011151340A 2002-12-18 2011-07-08 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法 Pending JP2012046489A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002953436 2002-12-18
AU2002953436A AU2002953436A0 (en) 2002-12-18 2002-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004559490A Division JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法

Publications (2)

Publication Number Publication Date
JP2012046489A JP2012046489A (ja) 2012-03-08
JP2012046489A5 true JP2012046489A5 (https=) 2012-10-11

Family

ID=30004521

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004559490A Pending JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法
JP2011151340A Pending JP2012046489A (ja) 2002-12-18 2011-07-08 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004559490A Pending JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法

Country Status (11)

Country Link
US (2) US7485292B2 (https=)
EP (1) EP1581257B1 (https=)
JP (2) JP2006517189A (https=)
KR (1) KR101171295B1 (https=)
CN (2) CN102166228B (https=)
AU (1) AU2002953436A0 (https=)
CA (1) CA2510227C (https=)
ES (1) ES2463678T3 (https=)
NZ (1) NZ541230A (https=)
WO (1) WO2004054613A1 (https=)
ZA (1) ZA200505389B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
CA2577692C (en) 2004-08-20 2014-05-06 Viralytics Limited Methods and compositions for treatment of hematologic cancers
WO2006074526A1 (en) * 2005-01-17 2006-07-20 Viralytics Limited Method and composition for treatment of neoplasms
EP2851078B1 (en) * 2012-04-19 2017-06-07 Kyushu University, National University Corporation Pharmaceutical composition
EP2826856B9 (en) 2013-07-16 2016-05-04 Sia Latima Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
RU2682762C2 (ru) * 2013-11-27 2019-03-21 Общество С Ограниченной Ответственностью "Панацела Лабс" Улучшенный вектор, экспрессирующий toll-подобный рецептор и агонист, и применение в терапии рака
WO2015127501A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
CN103981152B (zh) * 2014-04-16 2015-01-21 武汉博威德生物技术有限公司 一种柯萨奇病毒及其制备抗肿瘤药物之应用
EP4023233B1 (en) 2016-09-27 2026-01-07 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
EP3610870A4 (en) * 2017-03-31 2020-12-09 Ogata, Hisanobu METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT
CN109419818B (zh) * 2017-08-24 2021-08-10 厦门大学 一种用于治疗肿瘤的埃可病毒
CN107669707A (zh) * 2017-11-16 2018-02-09 邹罡 埃可病毒作为溶瘤病毒在抗肿瘤中的应用
EP3880812A4 (en) * 2018-11-13 2022-09-07 Oncorus, Inc. ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113421A (en) * 1978-02-24 1979-09-05 Fumiaki Taguchi Large scale cultivation of virus
US5585254A (en) * 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
JPH04504361A (ja) 1989-04-05 1992-08-06 ノバセル　コーポレイション 感染性標的化複製―欠陥ビリオン
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1993000442A1 (en) * 1991-06-24 1993-01-07 The Research Foundation Of State University Of New York De novo cell-free synthesis of picornavirus
JPH06509578A (ja) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
ATE199568T1 (de) 1993-02-16 2001-03-15 Onyx Pharma Inc Cytopatische viren zur therapie und prophylaxe der neoplasie
EP2009119A1 (en) 1993-04-30 2008-12-31 Wellstat Biologics Corporation Compositions for treating cancer using viruses
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
CA2323067A1 (en) 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
US6060316A (en) * 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
DE60039730D1 (de) 1999-02-05 2008-09-11 Arch Dev Corp Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
AU2005201079C1 (en) 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
JP2003530301A (ja) 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
EP1067188A1 (en) 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
DE19939095A1 (de) 1999-08-18 2001-02-22 Univ Eberhard Karls Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer
NZ517573A (en) 1999-09-17 2004-02-27 Pro Virus Inc Sequences of the oncolytic virus strain vesicular stromatitis virus (VSV)
EP1955703A1 (en) 1999-11-12 2008-08-13 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
ES2288488T3 (es) 1999-11-15 2008-01-16 Onyx Pharmaceuticals, Inc. Adenovirus oncoliticos.
AU2004202292B2 (en) 1999-11-25 2007-06-14 Viralytics Limited Method of Treating a Malignancy in a Subject
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU770517B2 (en) 1999-11-25 2004-02-26 Viralytics Limited A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
DE60115600T2 (de) 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
EP1286678A2 (en) 2000-06-01 2003-03-05 Sloan-Kettering Institute For Cancer Research Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer
JP2004519431A (ja) 2000-12-01 2004-07-02 ユニバーシティ・オブ・オタワ 腫瘍溶解性ウイルス
AU2002318104A1 (en) * 2001-01-05 2002-11-25 Corixa Corporation Microparticles and methods for delivery of recombinant viral vaccines
WO2002087625A1 (en) 2001-05-02 2002-11-07 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
US7264814B2 (en) 2001-05-09 2007-09-04 M's Science Corporation Composition and method for treating cancer using herpes virus
EP1385466B1 (en) 2001-05-11 2011-03-09 Wellstat Biologics Corporation Oncolytic virus therapy
CA2352439A1 (en) 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
EP1409653A4 (en) 2001-07-23 2006-05-03 Onyx Pharma Inc IN HUMAN TARGET CANCELLS SELECTIVELY REPLICATING VIRUS MUTANTS
AU2003216502B2 (en) 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
AU2003258060B2 (en) 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
EP1499332A4 (en) 2002-04-29 2006-12-06 Hadasit Med Res Service COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A VIRAL ONCOLYTIC AGENT
DE03722131T1 (de) 2002-05-09 2005-09-15 Oncolytics Biotech, Inc., Calgary Methode zur schmerzbekämpfung mit onkolytischen viren
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005002607A2 (en) 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
US20070036758A1 (en) 2003-07-08 2007-02-15 Bertram Jacobs Mutants of vaccinia virus as oncolytic agents
WO2005030139A2 (en) 2003-09-26 2005-04-07 Novartis Ag Seneca valley virus based compositions and methods for treating disease
AU2005221725B2 (en) 2004-03-11 2010-06-24 Viralytics Limited Modified oncolytic viruses
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US8080240B2 (en) 2004-10-21 2011-12-20 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells

Similar Documents

Publication Publication Date Title
JP2012046489A5 (https=)
Roy et al. Lycorine: A prospective natural lead for anticancer drug discovery
Marcucci et al. How to improve exposure of tumor cells to drugs—Promoter drugs increase tumor uptake and penetration of effector drugs
NZ717490A (en) Methods of treating cancer
Bouche Compression and entrapment neuropathies
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
JP2014530873A5 (https=)
JP2013155188A5 (https=)
NZ707377A (en) Combination therapy methods for treating proliferative diseases
ECSP109969A (es) Terapia especifica y medicamento que usan ligando de integrina para tratar cancer
HK1210699A1 (en) Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
JP2018522028A5 (https=)
JP2014523398A5 (https=)
JP2015507020A5 (https=)
JP2015506352A5 (https=)
JP2015044878A5 (https=)
UA100883C2 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
CN103239464A (zh) 淫羊藿次苷ii在制备肿瘤化疗药物增敏剂中的用途
JP2015500286A5 (https=)
Luo et al. Baicalein exerts antitumor effect in cervical cancer
JP2015529664A5 (https=)
Isakoff et al. Abstract OT2-3-07: A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer
Gholami et al. Enhanced therapeutic effects of a novel oncolytic and anti-angiogenic vaccinia virus against triple-negative breast cancer
Mierzejewska et al. Novel evidence that hematopoietic stem/progenitor cells (HSPCs) are mobilized during hemolysis in an erythrocyte lysis-derived, sphingosine-1-phosphate (S1P)-dependent manner—the crucial involvement of complement cascade (CC) activation and attenuation of CXCR4 retention signaling
Marzuillo et al. Ondasetron Is More Likely Than Ketamine to Cause Ventricular Tachycardia